SCY-078 Displays Potent In Vitro Activity Against Candida glabrata Isolates with Mutations in fks Gene

The Novel Oral Glucan Synthase Inhibitor SCY-078 Shows In Vitro Activity Against Candida spp. Bioflms

Activity of SCY-078 against Candida spp. obtained by EUCAST and CLSI procedures

Effect of SCY-078 on the Pharmacokinetics of Tacrolimus: Results from a Phase 1 Clinical Drug-Drug Interaction Trial

Effect of SCY-078 on the Pharmacokinetics of CYP2C8 substrate (Rosiglitazone) – Results from a Phase 1 Clinical Trial

Evaluation of Antifungal Activity of SCY-078 in Combination with Other Antifungals Against Aspergillus Strains

In vitro Interaction between SCY-078, Echinocandins and Azoles against Susceptible & Resistant Candida spp. Determined by the Checkerboard Method

Lack of an Effect of SCY-078, a Novel Antifungal Agent on QTc Interval in Healthy Subjects

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Panel of Susceptible and Resistant, Clinical Candida Isolates from Europe

Vaginal Concentrations of SCY-078, a Novel Glucan Synthase Inhibitor, Following Oral Administration in Mice